Martin Frejno

Martin Frejno

Auto-generated profile, based on publicly available information

Martin Frejno

MSAID Gmbh

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2019 in Molecular Systems Biology
Verified
Journal Article
Open access
PDF file
DWDongxue Wang
Dongxue Wang
BEBasak Eraslan
Basak Eraslan
TWThomas Wieland
Thomas Wieland
BHBjörn Hallström
Björn Hallström
THThomas Hopf
Thomas Hopf
BKBernhard Kuster
Bernhard Kuster
Genome‐, transcriptome‐ and proteome‐wide measurements provide insights into how biological systems are regulated. However, fundamental aspects relating to which human proteins exist, where they are expressed and in which quantities are not fully understood. Therefore, we generated a quantitative proteome and transcriptome abundance atlas of 29 paired healthy human tissues from the Human Protein Atlas project representing human genes by 18,072 transcripts and 13,640 proteins including 37 without prior protein‐level evidence. The analysis revealed that hundreds of proteins, particularly in testis, could not be detected even for highly expressed mRNAs, that few proteins show tissue‐specific expression, that strong differences between mRNA and protein quantities within and across tissues exist and that protein expression is often more stable across tissues than that of transcripts. Only 238 of 9,848 amino acid variants found by exome sequencing could be confidently detected at the protein level showing that proteogenomics remains challenging, needs better computational methods and requires rigorous validation. Many uses of this resource can be envisaged including the study of gene/protein expression regulation and biomarker specificity evaluation.

11 March 2020 in Nature
Verified
Journal Article
Closed access
PDF file
JMJulia Mergner
Julia Mergner
MFMartin Frejno
Martin Frejno
MLMarkus List
Markus List
MPMichael Papacek
Michael Papacek
XCXia Chen
Xia Chen
BKBernhard Kuster
Bernhard Kuster

20 July 2020 in Nature Communications
Verified
Journal Article
Open access
PDF file
MFMartin Frejno
Martin Frejno
CMChen Meng
Chen Meng
BRBenjamin Ruprecht
Benjamin Ruprecht
TOThomas Oellerich
Thomas Oellerich
SSSebastian Scheich
Sebastian Scheich
BKBernhard Kuster
Bernhard Kuster
Integrated analysis of genomes, transcriptomes, proteomes and drug responses of cancer cell lines (CCLs) is an emerging approach to uncover molecular mechanisms of drug action. We extend this paradigm to measuring proteome activity landscapes by acquiring and integrating quantitative data for 10,000 proteins and 55,000 phosphorylation sites (p-sites) from 125 CCLs. These data are used to contextualize proteins and p-sites and predict drug sensitivity. For example, we find that Progesterone Receptor (PGR) phosphorylation is associated with sensitivity to drugs modulating estrogen signaling such as Raloxifene. We also demonstrate that Adenylate kinase isoenzyme 1 (AK1) inactivates antimetabolites like Cytarabine. Consequently, high AK1 levels correlate with poor survival of Cytarabine-treated acute myeloid leukemia patients, qualifying AK1 as a patient stratification marker and possibly as a drug target. We provide an interactive web application termed ATLANTiC (http://atlantic.proteomics.wzw.tum.de), which enables the community to explore the thousands of novel functional associations generated by this work.

20 May 2021 in Rapid Communications in Mass Spectrometry
Verified
Journal Article
Closed access
PDF file
DZDaniel P. Zolg
Daniel P. Zolg
SGSiegfried Gessulat
Siegfried Gessulat
CPCarmen Paschke
Carmen Paschke
MGMichael Graber
Michael Graber
MRMagnus Rathke‐Kuhnert
Magnus Rathke‐Kuhnert
MFMartin Frejno
Martin Frejno

16 June 2022 in Nature Methods
Verified
Journal Article
Closed access
PDF file
PGPiero Giansanti
Piero Giansanti
PSPatroklos Samaras
Patroklos Samaras
YBYangyang Bian
Yangyang Bian
CMChen Meng
Chen Meng
ACAndrea Coluccio
Andrea Coluccio
BKBernhard Kuster
Bernhard Kuster

8 January 2019 in Proteomes
Verified
Journal Article
Open access
PDF file
JRJulia Rechenberger
Julia Rechenberger
PSPatroklos Samaras
Patroklos Samaras
AJAnna Jarzab
Anna Jarzab
JBJuergen Behr
Juergen Behr
MFMartin Frejno
Martin Frejno
BKBernhard Kuster
Bernhard Kuster
The microbiome has a strong impact on human health and disease and is, therefore, increasingly studied in a clinical context. Metaproteomics is also attracting considerable attention, and such data can be efficiently generated today owing to improvements in mass spectrometry-based proteomics. As we will discuss in this study, there are still major challenges notably in data analysis that need to be overcome. Here, we analyzed 212 fecal samples from 56 hospitalized acute leukemia patients with multidrug-resistant Enterobactericeae (MRE) gut colonization using metagenomics and metaproteomics. This is one of the largest clinical metaproteomic studies to date, and the first metaproteomic study addressing the gut microbiome in MRE colonized acute leukemia patients. Based on this substantial data set, we discuss major current limitations in clinical metaproteomic data analysis to provide guidance to researchers in the field. Notably, the results show that public metagenome databases are incomplete and that sample-specific metagenomes improve results. Furthermore, biological variation is tremendous which challenges clinical study designs and argues that longitudinal measurements of individual patients are a valuable future addition to the analysis of patient cohorts.